Motives for new psychoactive substances consumption among young adults in Uzbekistan: a qualitative study protocol

Abstract

BACKGROUND: New psychoactive substances (NPS) represent a global problem, especially among young people. In Central Asia, while the trafficking in NPS continues to grow, there remains a lack of data on the social, health and psychological consequences of their use.

AIM: To investigate the motives behind the NPS use among young people in the Republic of Uzbekistan, as well as the medical and social characteristics of this group.

METHODS: The study will include young people (18–35 years) who have used NPS in the preceeding 30 days (on the basis of self-reports) or are undergoing rehabilitation and plan to cease the NPS use within the next 12–18 months. Semi-structured interviews will reveal the reasons for NPS use, risk perception, stigma, barriers to seeking help, and the need for preventive and rehabilitation services. Interviews will take place at the Republican Mental Health Center and two specialized rehabilitation centers in Uzbekistan between November 2024 and the completion of enrollment (25–30 participants), but no later than May 2025. Additionally, a focus group of psychiatrists, psychotherapists, narcologists, and psychologists will evaluate the level of awareness amongst health care professionals as regards of NPS use and its prevalence, medical, and social implications.

EXPECTED RESULTS: The study will identify the key motives of NPS use, usage patterns, and social and medical barriers of help-seeking. Findings will contribute to the development of prevention and rehabilitation strategies, including digital communication platforms and interactive educational programs.

CONCLUSION: The study focuses on raising awareness about the consequences of NPS in the Republic of Uzbekistan. This is essential for developing effective public health prevention and rehabilitation programs.

Keywords

new psychoactive substances / youth / study protocol / Uzbekistan / qualitative study

References

[1] Peacock A, Bruno R, Gisev N, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;394(10209):1668–1684. doi: 10.1016/S0140-6736(19)32231-7

[2] Prilutskaya M, Sadvakassova G, Altynbekov K, et al. Inpatient Care for People with New Psychoactive Substance use Disorders: A Trend Study. Journal of Health Development. 2024;55(1):50–58. doi: 10.32921/2225-9929-2024-1-55-50-58

[3] Altynbekov KS, Negai NA, Abetova AA. [Methodology and results of a national study on the consumption of psychoactive substances among young people in the Republic of Kazakhstan]. Vestnik KazNMU. 2021;(4):193–201. Russian.

[4] Pisarska A, Deluca P, Demetrovics Z, et al. Novel psychoactive substances (NPS) – knowledge and experiences of drug users from Hungary, Poland, the UK and the USA. Neuropsychopharmacol Hung. 2019;21(4):152–163.

[5] Benschop A, Urban R, Kapitany-Foveny M, et al. Why do people use new psychoactive substances? Development of a new measurement tool in six European countries. J Psychopharmacol. 2020;34(6):600–611. doi: 10.1177/0269881120904951

[6] Gittins R, Guirguis A, Schifano F, et al. Exploration of the Use of New Psychoactive Substances by Individuals in Treatment for Substance Misuse in the UK. Brain Sci. 2018;8(4):58. doi: 10.3390/brainsci8040058

[7] Coombs T, Ginige T, Van Calster P, et al. New Psychoactive Substances in the Homeless Population: A Cross-Sectional Study in the United Kingdom. Int J Ment Health Addict. 2023;22(4):2322–2237. doi: 10.1007/s11469-022-00988-7

[8] O’Neill N. Mephedrone and Multiplicity: User Accounts of Effects and Harms. Contemp Drug Probl. 2014;41(3):417–444. doi: 10.1177/009145091404100307

[9] Assi S, Gulyamova N, Ibrahim K, et al. Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies. Hum Psychopharmacol. 2017;32(3). doi: 10.1002/hup.2607

[10] Higgins KM, O’Neill C, O’Hara L, et al. Evidence for public health on novel psychoactive substance use: a mixed-methods study. Public Health Res. 2019;7(14):1–150. doi: 10.3310/phr07140

[11] Papanti D, Schifano F, Botteon G, et al. “Spiceophrenia”: a systematic overview of “spice”-related psychopathological issues and a case report. Hum Psychopharmacol. 2013;28(4):379–389. doi: 10.1002/hup.2312

[12] Daziani G, Lo Faro AF, Montana V, et al. Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review. Int J Mol Sci. 2023;24(7):6230. doi: 10.3390/ijms24076230

[13] Bilel S, Zamberletti E, Caffino L, et al. Cognitive dysfunction and impaired neuroplasticity following repeated exposure to the synthetic cannabinoid JWH-018 in male mice. Br J Pharmacol. 2023;180(21):2777–2801. doi: 10.1111/bph.16164

[14] Deluca P, Davey Z, Corazza O, et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuro-psychopharmacol Biol Psychiatry. 2012;39(2):221–226. doi: 10.1016/j.pnpbp.2012.07.011

[15] Chiappini S, Mosca A, Miuli A, et al. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. Medicina (Kaunas). 2021;57(6):580. doi: 10.3390/medicina57060580

[16] Wieczorek Ł, Dabrowska K, Bujalski M. Motives for using new psychoactive substances in three groups of Polish users: nightlife, marginalised and active on the In. Psychiatr Pol. 2022;56(3):453–470. doi: 10.12740/PP/131971

[17] Ricijaš N, Kranželić V, Leskovar L. Prevalence and the frequency of psychoactive substance consumption of youth in educational institutions — differences with regards to the type of institution and knowledge about psychoactive substances. Kriminologija & Socijalna Integracija. 2019;27(1):35–67. doi: 10.31299/ksi.27.1.2

[18] Schijven EP, Didden R, Otten R, et al. Substance use among individuals with mild intellectual disability or borderline intellectual functioning in residential care: Examining the relationship between drinking motives and substance use. J Appl Res Intellect Disabil. 2019;32(4):871–878. doi: 10.1111/jar.12578

[19] Macgowan MJ, Engle B. Evidence for optimism: behavior therapies and motivational interviewing in adolescent substance abuse treatment. Child Adolesc Psychiatr Clin N Am. 2010;19(3):527–545. doi: 10.1016/j.chc.2010.03.006

[20] Agerwala SM, McCance-Katz EF. Integrating screening, brief intervention, and referral to treatment (SBIRT) into clinical practice settings: a brief review. J Psychoactive Drugs. 2012;44(4):307–317. doi: 10.1080/02791072.2012.720169

[21] Jatau AI, Sha’aban A, Gulma KA, et al. The Burden of Drug Abuse in Nigeria: A Scoping Review of Epidemiological Studies and Drug Laws. Public Health Rev. 2021;42:1603960. doi: 10.3389/phrs.2021.1603960

[22] Bandura A. Social foundations of thought and action: a social cognitive theory. Englewood Cliffs: Prentice-Hall; 1986.

[23] Syunyakov T, Khayredinova I, Ashurov Z. The Role of Family, Microsocial and Medical History in The Shaping of Trajectories of Complex Opioid and Cannabis Addiction: Results of Machine Learning Modeling. Personalized Psychiatry and Neurology. 2023;3(2):120–133. doi: 10.52667/2712-9179-2023-3-2-120-133

Funding

Federal Ministry for Economic Cooperation and Development (BMZ)Федеральное министерство экономического сотрудничества и развития

RIGHTS & PERMISSIONS

Zakhidova G.A., Pikirenia U.I., Syunyakov T.S., Prilutskaya M.V.